Ex-Siemens Business Development Manager joins Manus

Manus Neurodynamica Limited

Ex-Siemens Business Development Manager joins Manus

Director of Commercial Growth appointed to execute sales and marketing strategy

Edinburgh, UK – 18 March 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the appointment of Euan Donald as Director of Commercial Growth with immediate effect, where he will be responsible for developing and executing Manus’ sales and marketing strategy.

Euan has provided leadership in sales, marketing and product management for over 20 years in highly competitive hospital and veterinary markets, where he created marketing strategies and led sales efforts. Euan successfully developed opportunities in new business areas, created new partnerships and established significant revenue growth.

Euan joins Manus from Siemens Diagnostics UK, where as Business Development Manager, he was responsible for generating new business opportunities leading to increased sales and provided a clinical and scientific knowledge base for complex tender discussions. Prior to this Euan was International Manager at Nova Biomedical USA, managing 35 distributors into the EU, where he achieved increased revenue and demonstrated improved profile for the business.

Dr Rutger Zietsma, Chief Executive Officer of Manus Neurodynamica, said: “We are extremely pleased to welcome Euan onto the Manus Team, at a time of great progress for the Company as we set to roll-out our NMP later this year. Euan’s expertise in sales and marketing and commercial acumen will be invaluable to the business as we bring our product to market enabling clinicians to streamline the care pathway improving people’s health and wellbeing. His experience in launching new products and building sales teams is going to be paramount to the forward progression of the business.”

Euan Donald, Director of Commercial Growth at Manus Neurodynamica, said: “I am delighted to join the team at Manus and work with such an innovative Company with a product which could help transform the patient’s interactions with the healthcare system. I truly believe there is nothing like the NeuroMotor PenTM on the market and I look forward to bringing my experience and knowledge of developing diagnostics solutions to influence care pathways to Manus, supporting the Company on its next phase of growth.”


Manus Neurodynamica Ltd
Dr Rutger Zietsma, Chief Executive Officer             
0131 563 5465
Walbrook PR (PR advisors to Manus)
Lianne Cawthorne / Anna Dunphy
+44 20 7933 8780 or lifesciences@walbrookpr.com
+44 7584 391 303 / +44 7876 741 001

Notes to Editors

About Manus Neurodynamica – www.manusneuro.com

Dr Rutger Zietsma founded Manus in August 2008. The Company’s main activity is designing, patenting and marketing innovative technologies used in medical devices and personal care products which have the capability to improve people’s health and wellbeing. The Company implements quality procedures to medical standards.

Its principal product is a sensory pen designed for use in the diagnosis and monitoring of neuromotor impairments. The pen particularly focuses on patients with Parkinson’s disease and uses limb and hand motion to diagnose patients quickly and non-invasively. It has applications across not just diagnosis but also screening, monitoring, rehabilitation and drug development for a number of different movement disorders.

About NeuroMotor PenTM

NeuroMotor Pen™ (NMP) is a unique, patented and CE-marked system that combines sensor technologies built into a digital pen with software and an analytical engine with Decision Support System. The interface enables users to record non-invasively and analyse parameters of minute limb and hand motion. This enables quantification of fine motor skill. These parameters are used as ‘digital biomarkers’ to provide objective information about movement abnormalities. NMP can be used to support diagnosis and monitoring of Parkinson’s Disease and other neuromotor impairments. It has the potential to be a quick, inexpensive, non-invasive, and objective aid to diagnosis that can provide a low-cost alternative to brain scans.

Click here to download the Press Release (pdf)